Physician profile
Sheldon Jon Harigel
NPI 1407090731
$2,419.20
in general payments reported to CMS, 2019-2025
30 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,025 · 2020: $81.48 · 2021: $130 · 2022: $506 · 2023: $254 · 2024: $169 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $447.21 | 2021-2024 | |
| Novo Nordisk INC | $351.24 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $196.00 | 2019-2024 | Xarelto |
| Allergan, INC. | $159.65 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $156.31 | 2019-2023 | |
| Lilly USA, LLC | $116.59 | 2019-2025 | Mounjaro |
| Medtronic, INC. | $115.18 | 2022-2025 | Inceptiv |
| Pfizer INC. | $111.07 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $91.79 | 2019-2025 | Airsupra |
| Abbott Laboratories | $76.74 | 2021-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $73.82 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $45.67 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $44.12 | 2019-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.99 | 2022-2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $37.48 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.32 | 2025 | Caplyta |
| Mylan Specialty L.P. | $34.25 | 2019 | |
| Philips North America LLC | $30.94 | 2024-2025 | (Ck7) Extended Holter, Extended Holter |
| Shire North American Group INC | $29.71 | 2019 | |
| Glaxosmithkline, LLC. | $28.10 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.35 | 2019 | |
| Orexo US, INC. | $25.97 | 2019 | |
| Alnylam Pharmaceuticals INC. | $25.81 | 2025 | Givlaari |
| Paratek Pharmaceuticals, INC. | $22.29 | 2024 | Nuzyra |
| Phathom Pharmaceuticals, INC. | $22.16 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $17.55 | 2023 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $14.45 | 2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $14.38 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.20 | 2019 | |
| Dexcom, INC. | $12.86 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldon Harigel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.